API | imiglucerase

imiglucerase (cerezyme) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG repoDB

Active Ingredient History

NOW

Now

Imiglucerase is a medication used in the treatment of Gaucher's disease. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

imiglucerase

velaglucerase alfa

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$250.2575 - $1488.8400

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

cerezyme | d-glucosyl-n-acylsphingosine glucohydrolase | ec 3.2.1.45 | ga-gcb | glucosylceramidase | isu302 | velaglucerase alfa | velaglucerase-alfa | vpriv

Organizations (31)

Research & Development (31)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (3)

Gaucher Disease

Thrombocytopenia

Experimental Indications - Clinical Trial Phases 1-4 (2)

Deficiency Diseases (Phase 4)

Gaucher Disease ()

Overview

Highest Phase: Phase 4
# of Trials: 26
# of Trial Organizations: 31

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue